Market Views – Page 13 – media

How do Clinical Wearables Impact Patient Care and Quality of Life?

Health technology and clinical wearables are hot topics in the healthcare and pharmaceutical industries. They are creating waves of excitement and talking points for debate, while also topping many of the healthcare trends of this year.
- Source: Hit Consultant
- 1,029
- April 10, 2018
Market Views mHealth wearables
Where AI has the most promise for reducing healthcare costs

AI technology is already in use in certain aspects of healthcare, such as diagnostic imaging, but it’s being underutilized in several others.
- Source: HealthcareITNews
- 720
- April 10, 2018
AI digital health EHR Market Views
Novo moves into sickle cell with $400M EpiDestiny deal

Novo Nordisk has moved into sickle cell disease through a licensing deal (PDF) with EpiDestiny. The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.
- Source: Fiercebiotech
- 707
- April 9, 2018
epigenetic Market Views sickle cell disease
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
- Source: Businesswire;
- 595
- April 9, 2018
acquisition CDI Market Views non-antibiotic
Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
- Source: finance.yahoo
- 515
- April 8, 2018
CAR-T therapy immuno-oncology Market Views
Macrolide Pharmaceuticals Appoints New President and CEO Raises $20 Million in Investor Financing by Allyson English

Macrolide Pharmaceuticals, a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity for a broad range of multi-drug resistant bacterial infections, announced that Mahesh Karande has joined the company as President and CEO. The company is also pleased to announce the completion of a $20 million financing led by current investors Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Venture Fund and SR One.
- Source: macrolide
- 460
- April 8, 2018
macrolide antibiotics Market Views
Singapore’s Aslan stalks $86M IPO to fund cancer pipeline

Aslan wants to list on the U.S. exchange under the ASLN symbol.
- Source: fiercebiotech
- 545
- April 5, 2018
Aslan Market Views varlitinib
Another immunometabolism deal? Johns Hopkins spinout Dracen lands $36M investment from Deerfield

The company, founded just a year ago, is developing novel glutamine antagonists that work as inhibitors of cancer metabolism, choking out tumors and their normal metabolic function.
- Source: Endpts
- 596
- April 3, 2018
cancer inhibitor Market Views metabolism
Nine digital health mergers and acquisitions from the first quarter of 2018

The first quarter of 2018 was light on mergers and acquisitions compared to previous quarters, but those that did crop up were significant, including major companies like Fitbit, Allscripts, Roche, and Johnson & Johnson.
- Source: MobiHealthNews
- 496
- April 2, 2018
digital health Market Views merger-and-acquisition
Third Rock debuts immunometabolism startup Rheos with $60M launch round

Global pharmaceutical company Mylan N.V. (MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.
- Source: pharmacompass
- 633
- March 30, 2018
financing immune Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.